Pentadecapeptide BPC (Stable Oral)
Pending PCACAlso known as: BPC Stable Oral, PL 10, Pentadecapeptide
Healing & RecoveryLast reviewed: April 28, 2026
A stabilized oral formulation of the BPC-157 pentadecapeptide sequence designed for gastrointestinal applications. Unlike standard BPC-157 which is typically injected, this formulation uses stabilization techniques to survive gastric acid degradation. Primarily studied for gut healing, ulcer protection, and inflammatory bowel conditions.
Mechanism of Action
Same core mechanism as BPC-157 — upregulates growth factor expression (VEGF, EGF), promotes angiogenesis, and modulates the nitric oxide system. The oral formulation targets the GI tract directly, providing local healing effects on the gastric and intestinal mucosa before systemic absorption.
Common Uses
- Gut healing and repair
- Gastric ulcer protection
- Inflammatory bowel support
- Leaky gut syndrome (investigational)
- NSAID-induced GI damage protection
Known Risks
- Limited human clinical data
- GI discomfort possible
- Uncertain bioavailability compared to injectable
- Quality varies significantly between suppliers
- Not FDA-approved for any indication
Regulatory Status
Shares regulatory status with BPC-157. Removed from Category 2 on April 22, 2026. Awaiting PCAC review at the July 23, 2026 meeting. The oral formulation is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
Get notified when the PCAC decides on Pentadecapeptide BPC (Stable Oral)
Scheduled review: 2026-07-23. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Oral capsule or liquid
Typical Dose
250–500 mcg
Frequency
Once or twice daily on empty stomach
Cycle Length
4–8 weeks
Take 30 minutes before meals for best absorption. The oral route primarily targets GI tract healing. For systemic effects (tendons, joints), injectable BPC-157 is generally preferred. Some practitioners combine oral and injectable forms for comprehensive protocols.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.